

February 07, 2017

BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001

Sub: Press Release

Dear Sir/Madam,

Please find enclosed the Press Release issued in connection with Unaudited Financial Results of the Company for the quarter ended December 31, 2016.

Kindly take it on your records.

Thanking you,

Yours faithfully,



L Chandrasekar
Executive V P – Finance & Secretary.

Encl.: a/a



BSE: 524372 NSE: ORCHIDPHAR Bloomberg: ORCP:IN Reuters: ORCD.BO

Q3 FY 2016-17 Earnings

Chennai, India – February 7, 2017

Orchid Pharma registers turnover of Rs 179.98 crore in Q3 FY 2016-17, EBITDA of Rs 41.49 crore.

Financial highlights for Quarter ended December 31, 2016 (Q3 FY 2016-17) – Standalone

- Revenue of Rs 179.98 crore (US\$ 26.3 million) in the quarter ended December 31, 2016 (Q3 FY 2016-17) as compared to Rs 205.88 crore (US\$ 30.1 million) registered during the quarter ended December 31, 2015 (Q3 FY 2015-16).
- EBITDA of Rs 41.49 crore (US\$ 6.1 million) in the quarter ended December 31, 2016 as compared to Rs 38.62 crore (US\$ 5.6 million) in the quarter ended December 31, 2015.
- At the net level, the company registered a loss of Rs 60.98 crore (US\$ 8.9 million) during the quarter ended December 31, 2016 as compared to a loss of Rs 94.02 crore (US\$ 13.7 million) for the corresponding quarter ended December 31, 2015.

*** 1 US\$ = Rs 68.39**

For ORCHID PHARMA LTD.


Executive VP - Finance & Secretary